Introduction
With a prevalence of one in 3000-4000 newborns, congenital hypothyroidism is the most common inborn endocrine disorder and a common cause of preventable mental retardation. Although most cases are sporadic and associated with abnormalities of thyroid gland development and migration (thyroid dysgenesis), 15-20% are caused by inherited defects in one of the steps of thyroid hormone synthesis (thyroid dyshormonogenesis) ( Fig. 1 ). When the synthesis defect results in reduced hormone secretion, the ensuing diminished negative feedback on the anterior pituitary thyrotrophs leads to an increase in thyrotropin (TSH) secretion stimulating the thyroid gland. Consequently, patients are either born with an enlarged thyroid gland (goiter) or develop goiter postnatally, especially when diagnosis and levothyroxine (L-T 4 ) supplementation are delayed. With the exceptions indicated below, these defects are inherited in an autosomal recessive fashion and are amenable to detection by the newborn screening for congenital hypothyroidism.
The etiological classification of congenital hypothyroidism is based on clinical and biochemical evaluation. Useful tests are measurement of serum TSH, thyroxine (T 4 ), triiodothyronine (T 3 ), and thyroglobulin; thyroid ultrasound and scintigraphy, using 99m pertechnetate or, preferably, 123 I [1] and, when indicated, the perchlorate (ClO 4 À ) discharge test. Often infants with congenital hypothyroidism, confirmed by the TSH and T 4 values, are started on thyroid hormone replacement without etiologic diagnosis. The latter is usually postponed until 2 or 3 years of age, following a 1-month withdrawal of L-T 4 replacement.
With the identification of the key steps involved in thyroid hormone synthesis, a molecular genetic diagnosis should be feasible for the vast majority of patients with dyshormonogenesis. A complete diagnostic workup facilitates the Purpose of review Overview of congenital hypothyroidism caused by thyroid hormone synthesis defects, the current understanding of their pathophysiology, and clinical implications of molecular diagnoses.
Recent findings
Genetic defects in all known thyroid-specific factors required for thyroid hormone synthesis have been described. These include defects in iodide trapping (NIS), in the facilitated iodide efflux across the apical membrane (PDS), the organification of iodide within the follicular lumen (thyroid peroxidase, DUOX2, DUOXA2), the substrate for thyroid hormone synthesis (thyroglobulin) and the ability to recover and retain intrathyroidal iodine (iodotyrosine deiodinase). Clinical and biochemical evaluation aids in selecting the most appropriate candidate gene(s). A definite molecular diagnosis of thyroid dyshormonogenesis allows genetic counseling and has prognostic value in differentiating transient from permanent congenital hypothyroidism and predicting the response of patients to iodine supplementation as adjunct or alternative treatment to L-T 4 replacement.
Summary
Congenital hypothyroidism due to thyroid dyshormonogenesis is a heterogenic disorder that may be caused by mutations in any of the known steps in the thyroid hormone biosynthesis pathway. An exact molecular diagnosis allows genetic counseling and the identification of asymptomatic mutation carriers at risk of recurrent hypothyroidism, and provides a rationale for adjunct iodide supplementation. selection of the likely candidate gene(s) for genetic confirmation (Table 1) . Although the distinguishing features of each particular hormone synthesis defect are outlined in the following sections, it should be noted that early genetic screening might be justified even without complete clinical workup. Other than providing useful information for genetic counseling, there are additional benefits to a definite genetic diagnosis. One is the potential impact on treatment, as some defects may be efficiently treated with iodide supplementation rather than with L-T 4 . Another benefit is in the identification of a subset of patients with transient congenital hypothyroidism due to partial hormonogenesis defects. Even if they are euthyroid at a particular point in time, increased demand for thyroid hormone may precipitate hypothyroidism at another time. An early molecular diagnosis predicts the necessity for life-long hormone replacement therapy. Finally, some genetic defects may not manifest at birth but produce hypothyroidism later in life. The definitive diagnosis of an index case will enable early identification of subsequent cases in the same family and help to avoid the negative consequences associated with delayed diagnosis and treatment of hypothyroidism on mental development.
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Basolateral iodide transport defect due to mutations in the SLC5A5 (sodium iodide symporter) gene
The sodium iodide symporter (NIS; official gene symbol: SLC5A5) is a 13-transmembrane domain glycoprotein that mediates the uptake of iodide through the basolateral membrane of thyroid follicular cells ( Fig. 1 ). Iodide is 422 Endocrinology and metabolism
Key points
Congenital hypothyroidism due to hormone synthesis defects is heterogeneous, but amenable to precise molecular diagnosis. Clinical and biochemical evaluation aids in selecting the most appropriate candidate gene(s) among SLC5A5, SLC26A4, thyroid peroxidase, thyroglobulin, DUOX2, DUOXA2, and iodotyrosine deiodinase. A molecular diagnosis allows genetic counseling and the identification of asymptomatic mutation carriers at risk of recurrent hypothyroidism, and provides a rationale for adjunct therapy with iodide supplementation. The distinct steps comprise (1) the active uptake of iodide from the blood circulation via the sodium iodide symporter (SLC5A5); (2) the facilitated efflux of iodide into the colloid via an apical anion channel (SLC26A4); (3) iodination of tyrosine groups of thyroglobulin (TG) catalyzed by thyroid peroxidase (TPO); (4) subsequent coupling of iodinated tyrosines within TG via ether bond formation to iodothyronines; steps 3 and 4 require hydrogen peroxide as cosubstrate, which is provided by a hydrogen peroxide generating NADPH oxidase constituted by dual oxidase 2 (DUOX2) and its maturation factor (DUOXA2); (5) following endocytosis, iodothyronines (T4 > T3) are liberated by lysosomal degradation of the TG matrix protein; (6) concomitantly released iodotyrosines are dehalogenated by iodotyrosine deiodinase (IYD) allowing 'recycling' of iodide for further hormone synthesis. DIT, diiodotyrosine.
actively concentrated into these cells by the electrogenic symport of Na þ (2 Na þ for 1 I À ) down the electrochemical gradient maintained by the activity of Na þ /K þ -ATPase.
Shortly after cloning of the gene [2] , mutations in the SLC5A5 gene were described as cause of congenital iodide transport defect (ITD) [3] . The incidence is unknown, as the characteristic clinical findings of absent thyroidal iodide have led to the erroneous diagnosis of athyreosis, especially when goiter was absent or missed and when serum thyroglobulin was not measured. Individuals with ITD were found to be homozygous or compound heterozygous for 13 different SLC5A5-inactivating mutations (V59E, G93R, R124H, Q267E, C272X, G395R, T354P, fs515X, Y531X, DelM143-Q323, DelV287-G288, DelA439-P443, and G543E) [4 ] . The onset of hypothyroidism has varied from birth to childhood and seems to correlate with the residual in-vitro activity of the mutant transporter [5] .
Scintigraphy reveals blunted or absent radioactive iodide uptake (RAIU) in a normally located thyroid gland. RAIU in ITD is 0-5% (normal 10-40%) and imaging may suggest athyreosis, especially when the presence of a thyroid gland is missed [6] . As the loss of SLC5A5 function is generalized, it also involves reduced iodide uptake in salivary glands and gastric parietal cells, and hence failure to visualize these organs during 123 I scintiscanning. Ultrasound examination further helps to distinguish defects in SLC5A5 from other conditions with reduced iodide uptake, as it shows, characteristically, a normally located enlarged thyroid gland, excluding thyroid gland hypoplasia due to TSH receptor defects.
Genetic screening should be considered in all patients with permanent goitrous hypothyroidism in conjunction with low or absent RAIU. Without RAIU results, patients with goitrous hypothyroidism associated with high serum thyroglobulin are better first evaluated for defects in thyroid peroxidase (TPO) and DUOX2. Apart from establishing a definite diagnosis, finding SLC5A5 gene mutations has further implications. Identification of an index case will allow subsequent preclinical diagnoses of other cases in the same family, as patients with delayed onset of congenital hypothyroidism in ITD had already signs of developmental delay at the time of diagnosis [5] . Concerning treatment options, iodide supplementation can improve thyroid function in patients with residual NIS activity and should be considered, either alone or together with L-T 4 replacement.
Defect in apical iodide efflux due to mutations in the SLC26A4 (PDS) gene
SLC26A4 is a member of the multifunctional SLC26 transporter family facilitating the passive efflux of iodide across the apical thyrocyte membrane into the follicular lumen ( Fig. 1 ). In the inner ear, chloride/bicarbonate exchange by SLC26A4 is crucial for acid-base homeostasis of the endolymphatic fluid.
Biallelic inactivating mutations of the SLC26A4 gene are a cause of Pendred syndrome (PDS) [7] . It is clinically Genetic causes of dyshormonogenesis Grasberger and Refetoff 423 defined by congenital bilateral sensorineural hearing loss (associated with vestibular dysfunction) combined with diffuse or multinodular goiter. The latter usually develops in late childhood or early adolescence and is the consequence of a partial iodide organification defect consistent with the function of SLC26A4 as an apical iodide efflux channel in thyrocytes. However, about half of patients with SLC26A4 defects do not manifest thyroid abnormalities (designated nonsyndromic hearing loss with familial enlarged vestibular aqueduct or DFNB4). Nutritional iodide intake is an important modifier of the thyroid phenotype in PDS. With sufficient dietary iodide, about 90% of patients are clinically and biochemically euthyroid. In the remaining 10% with elevated TSH level, goiter is always present [8] .
PDS is rarely detected by neonatal screening for congenital hypothyroidism [9] . Rather, patients present because of severe congenital deafness. In patients with congenital hypothyroidism, screening for mutations in the SLC26A4 gene is only justified when hearing impairment is present without the additional need to perform a ClO 4 À discharge test. Before systematic mutation scanning, targeted screening for the most common, recurrent mutations can be considered: L236P, T416P, and IVS8þ1G>A in whites of northern European descent [10, 11] and H723R in Japanese patients [12] .
Mutations in the thyroglobulin gene
Thyroglobulin, a glycoprotein homodimer of 660 kDa, is the most abundantly expressed protein in the thyroid gland. It is secreted into the follicular lumen where it functions as a matrix for hormone synthesis, providing tyrosyl groups, the noniodide component of thyroid hormone ( Fig. 1) . Iodinated thyroglobulin constitutes the storage pool for thyroid hormone and iodide.
Following the first description of an inactivating mutation in the thyroglobulin gene by Ieiri et al. [13] , at least 40 other mutations have been reported [14 ] . Defects in thyroglobulin as a cause of congenital hypothyroidism have been most extensively studied in Japanese, for whom the estimated incidence is 1 : 67 000 [15] , equivalent to nearly one-fourth to one-third of all cases with thyroid dyshormonogenesis.
Patients with biallelic thyroglobulin gene defects typically manifest elevated serum TSH levels on neonatal screening. Serum T 3 levels are usually disproportionately higher then T 4 concentrations, apparently because of increased intrathyroidal type 2 iodothyronine deiodinase activity [16] . Most typical is undetectable or very low serum thyroglobulin level despite the elevated serum TSH. Goiters are often remarkably large, although early treatment should prevent goitrogenesis. Scintigraphy shows high uptake in a typically enlarged thyroid gland. As the iodide organification process is not affected, there is no discharge after administration of ClO 4 À . In the absence of thyroglobulin, iodide is covalently bound to other proteins, such as albumin. Mild thyroglobulin secretion defects can manifest as compensated hypothyroidism (isolated hyperthyrotropinemia). Screening for thyroglobulin gene mutations may be justified when absent or an unexpectedly low serum thyroglobulin level is found in a patient with congenital hypothyroidism having an enlarged thyroid gland.
Defects in iodination and coupling of tyrosyl moieties due to mutations in the thyroid peroxidase gene
TPO is a thyroid-specific heme peroxidase anchored via a C-terminal transmembrane domain at the apical membrane surface of thyroid follicular cells ( Fig. 1 ). Using hydrogen peroxide as oxidative equivalents, TPO catalyzes the iodination of tyrosyl residues in thyroglobulin and the subsequent phenoxy ether bond formation between pairs of iodotyrosines to generate iodothyronines (T 4 and, to a lesser degree, T 3 
and reverse T 3 ).
Abramowicz et al. [17] demonstrated the first inactivating, biallelic mutation in the TPO gene. Defects in this gene appear to be the most frequent cause of inherited dyshormonogenesis with permanent congenital hypothyroidism [18, 19, 20 ] and are present in virtually all patients with permanent total iodide organification defects (TIODs; >90% ClO 4 À discharge) [21] . The incidence of TIODs owing to biallelic TPO defects has been estimated at 1 : 66 000 for a Dutch population [21] .
In about 20% of the cases with TIODs, only monoallelic defects of TPO are found, presumably due to unidentified cryptic mutations in unexamined intronic or regulatory regions of the gene. Indeed, in a patient with TIOD and single-allele mutation, TPO mRNA analysis of thyroid tissue obtained at surgery revealed monoallelic expression of only the mutant allele, indicating an unidentified defect on the other allele [22] . Although heterozygous TPO mutations do not directly result in abnormal thyroid function, such monoallelic defects may play a role as genetic susceptibility factor in transient hypothyroidism.
In a Chinese population, heterozygosity for a common TPO gene founder mutation (2268insT) is 16 times more common in infants with transient neonatal hypothyroidism [23] .
TPO is the indisputable candidate gene in patients with permanent TIOD. In contrast, nonsyndromic partial iodide organification defect (PIOD) is heterogeneous, including defects in the hydrogen peroxide generator driving TPO activity (see below). When ClO 4 À discharge test is not available, screening for TPO mutations is still reasonable. For instance, 10 of 53 unrelated Portuguese with permanent congenital hypothyroidism, orthotopic thyroid glands, and elevated serum thyroglobulin levels harbored TPO defects [18] . In an eastern European population with unusually high frequency of dyshormonogenesis (34% of congenital hypothyroidism), 18 of 39 apparently unrelated patients with permanent congenital hypothyroidism, normal or enlarged gland in situ, and normal or high serum thyroglobulin were found to have TPO gene mutations. In 12 patients, only a single heterozygous mutation (1273_1276dupGGCC) was detected [19] . The high prevalence of TPO gene mutations can also lead to pseudodominant inheritance of goitrous congenital hypothyroidism, as described for a family segregating three different TPO mutations [24] .
Finding TPO gene mutations in a neonate with congenital hypothyroidism indicates that the patient will require lifelong treatment with thyroid hormone and that future pregnancies should be carefully monitored for the presence of prenatal goiter. The latter can be detected by ultrasonography and treated by a single intra-amniotic injection of L-T 4 to prevent goiter-related dystocia and improve neurological development [25] .
Defects in hydrogen peroxide generation due to mutations in the DUOX2 or DUOXA2 genes
Hydrogen peroxide is the essential electron acceptor for the TPO-catalyzed iodination and coupling reactions. It is produced at the apical membrane of follicular thyroid cells by dual oxidase (DUOX)/dual oxidase maturation factor (DUOXA) NADPH oxidase complexes [26, 27] . The DUOX2-based enzyme appears to be most critical for maintaining normal thyroid function, as only mutations in DUOX2 and DUOXA2, but not DUOX1 or DUOXA1, genes have been identified as cause of congenital hypothyroidism.
Since the first description of DUOX2 gene mutations in patients with congenital hypothyroidism [28] , 28 different mutations have been reported [29 ] . About half of these are nonsense, frameshift, or splice site mutations predicting a dysfunctional enzyme lacking the C-terminal NADPH oxidase domain (G201fs, W414X, Y425X, R434X, L479fs, K530X, K628fs, Q686X, R701X, R842X, S965fs, Q1023X, Q1026X, g.IVS19-2A>C). Of the missense mutations (Q36H, R110Q, R376W, Y475C, D506N, A649E, H678R, E879K, R885Q, S911L, C1052Y, and G1518S), six have been studied in vitro and shown to cause either complete trafficking defects or partial defects in cell surface expression of an oxidase complex with normal or absent intrinsic activity [30, 31, 32 ] . On the basis of the finding of loss-of-heterozygosity for common polymorphisms, two groups recently identified larger deletions affecting the DUOX2 locus in congenital hypothyroidism patients [32 ,33 ] .
Although most dyshormonogenesis defects are inherited in an autosomal recessive fashion, a single defective DUOX2 allele suffices to cause congenital hypothyroidism. When patients with mono-allelic defects were re-evaluated at 3 years of age after withdrawal of L-T 4 , they often showed normal thyroid function tests, indicating that the congenital hypothyroidism was transient [28] . In addition, adult heterozygotes in these and other families with DUOX2 gene defects had normal serum TSH concentrations. In the absence of dominant negative effects of the mutant DUOX2 proteins [30] , these patients appear to have DUOX2 haploinsufficiency with manifestation limited to the neonatal period, when thyroid hormone synthesis requirements are highest.
Several studies have linked biallelic DUOX2 gene defects to permanent congenital hypothyroidism with PIOD. On the basis of the type of mutations (nonsense, frameshift) or the in-vitro study of missense mutations found in homozygous or compound heterozygous state in these patients, most are predicted to express no residual DUOX2 activity. In contrast to the complete inactivation of TPO, which consistently leads to TIOD, a complete loss of DUOX2 activity does not completely abrogate the ability to synthesize thyroid hormone [34] . Limited iodide organification is likely maintained by the activity of DUOX1, which is also expressed in thyrocytes, albeit at lower level.
The expressivity of DUOX2 gene defects is likely influenced by genetic background and may, at least in part, depend on the iodide intake. As iodination by TPO requires both iodide and hydrogen peroxide, a diet containing excessive amounts of iodide would lead to better utilization of hydrogen peroxide provided by DUOX1. Credence to an important role of iodide intake in expressivity of DUOX2 defects is provided by a report of two siblings compound heterozygous for the same DUOX2 gene mutations. In one sibling, perinatal iodine overload produced completely normal TSH levels in the early postnatal period [35] , indicating compensation of the defect.
Although the incidence of DUOX2 gene mutations in congenital hypothyroidism has not been determined, they appear to be frequent in patients with PIOD. For instance, seven of 20 such unrelated patients from Italy were found to have pathogenetic DUOX2 gene mutations [36] . Sequencing of the DUOX2 gene is therefore recommended in patients with nonsyndromic PIOD. In those with suspected nonsyndromic organification defect (normal-sized to enlarged thyroid gland with high serum thyroglobulin concentration) without confirmation by ClO 4 À discharge test, the TPO gene should be screened first, especially in cases where congenital hypothyroidism is profound. Concerning follow-up, patients with transient congenital hypothyroidism due to DUOX2 haploinsufficiency are at risk for recurrent hypothyroidism at times of increased hormonogenesis requirements, such as pregnancy. With regard to treatment after the neonatal period, we would advocate to assess iodide supplementation as an alternative to potentially lifelong L-T 4 replacement therapy.
In 2008, the first mutation in the DUOXA2 gene was reported in a nonconsanguineous Chinese patient with PIOD and mild, permanent congenital hypothyroidism [37 ] . The patient was homozygous for an Y246X nonsense mutation that resulted in a complete loss of DUOXA2 function in vitro. The frequency of Y246X homozygosity has been estimated at one out of 34 000 newborns in the Shanghai Chinese population. Heterozygous carriers of this mutation had normal thyroid function tests, including negative neonatal screening for congenital hypothyroidism and ClO 4 À discharge tests. Accordingly, in contrast to monoallelic DUOX2 gene mutations, the loss of a single DUOXA2 allele does not lead to haploinsufficiency. Apart from the intact DUOXA1/DUOX1 system, an additional mechanism for maintaining adequate hydrogen peroxide supply in patients with DUOXA2 deficiency is the partial activation of DUOX2 by DUOXA1, as demonstrated in vitro [37 ] .
A more complex genetic alteration of the DUOX/DUOXA system was recently found in an infant with transient congenital hypothyroidism born to euthyroid nonconsanguineous parents [33 ] . Genetic analysis revealed a C189R missense mutation on the maternal DUOXA2 allele causing complete loss of function in vitro. On the paternal allele, a large deletion comprising DUOX2, DUOXA2, and DUOXA1 genes was identified. Thus, in this patient, near normal thyroid function is maintained after the neonatal period despite having only a single functional DUOXA allele (maternal DUOXA1). The high degree of functional redundancy for defects in DUOXA is likely due to molar excess of DUOXA over DUOX protein in the endoplasmic reticulum, owing to reduced synthesis efficiency of the more complex DUOX subunit.
Defects in recycling of intrathyroidal iodine due to mutations in the iodotyrosine deiodinase (also known as DEHAL1) gene
The lysosomal proteolysis of endocytosed iodinated thyroglobulin liberates the iodothyronines (T 4 and T 3 ). However, most iodide contained in thyroglobulin is released as uncoupled monoiodotyrosine and diiodotyrosines (MIT and DIT, respectively). The latter are subject to NADPH-dependent reductive deiodination by iodotyrosine deiodinase (IYD), leading to formation of free iodide and tyrosine, both of which can be reutilized in hormone synthesis (Fig. 1) . In addition to the thyrocyte, the enzyme is expressed in liver and kidney. The expression in the latter tissue serves for the execution of a pathognomonic in-vivo test.
In 2008, mutations in IYD underlying impaired intrathyroidal dehalogenation were described in four unrelated consanguineous families [38 ,39 ] . Six affected individuals were homozygous for either a missense mutation (R101W, I116T, or A220T) or a combined missense/ deletion mutation c.315delCAT (resulting in replacement of both F105 and I106 by leucine at position 105). All mutations map to the flavin-binding domain and virtually abolished the capacity of IYD to dehalogenate MIT and DIT in vitro. Notably, one heterozygous carrier of A220T developed nonautoimmune goitrous hypothyroidism at 15 years of age, pointing to a possible dominant behavior of the mutation in some individuals [39 ] .
Loss of IYD activity prevents the normal intrathyroidal iodide 'recycling' and leads to excessive urinary secretion of MIT and DIT. As the resulting iodide deficiency may not manifest at birth, the reported patients with biallelic IYD mutations tested normal at neonatal screening for congenital hypothyroidism [38 ] . They subsequently came to medical attention at 1.5-8 years of age because of sequelae of untreated hypothyroidism. On scintigraphy, a very rapid and high initial uptake of 123 I in the enlarged thyroid is observed, followed by a relatively rapid spontaneous decline of the accumulated iodine without the administration of ClO 4 À . The detection of high urinary MIT and DIT by tandem mass spectroscopy may become a useful diagnostic test.
The incidence of IYD mutations is unknown. Although not a viable candidate gene for congenital hypothyroidism, a potential role for IYD variants in susceptibility to endemic goiter remains to be investigated. We suggest that screening of IYD may be considered in patients developing 'idiopathic' diffuse or multinodular goiter between the neonatal period and adolescence, whereas early and late images during 123 I scintigraphy are compatible with IYD defects. However, deficient nutritional iodide intake, as in areas of endemic goiter, dietary goitrogens, and autoimmune thyroid disease have to be excluded. An autosomal recessive inheritance pattern of the disorder, as well as consanguinity of the parents, would likely increase the yield of mutation screening. Anecdotal evidence indicates that iodine supplementation (Lugol's solution) is an effective alternative to L-T 4 treatment in IYD deficiency [40] .
Conclusion
The cloning of important genes involved in thyroid hormone synthesis provides the basis for a molecular diagnosis in patients with congenital hypothyroidism due to dyshormonogenesis. A genetic diagnosis is crucial to further explore the complete phenotype of these disorders. For instance, in analogy to studies on the DUOX homologue of invertebrates [41] , the high expression of human DUOX enzymes in the barrier epithelia of human intestine and airways may indicate a yet unrecognized role in innate immunity. For the clinician treating patients with thyroid dyshormonogenesis, a precise molecular diagnosis allows genetic counseling and identification of asymptomatic mutation carriers at risk for developing hypothyroidism, and identification of the subset of patients likely to respond to iodide supplementation (all SLC26A4, DUOX2, DUOXA2, and IYD defects, and partial defects in SLC5A5).
